General
Preferred name
HYDROXYUREA
Synonyms
hydroxycarbamide ()
nci-c04831 ()
nsc32065 ()
Hydrea ()
Hydroxylamine, N-carbamoyl- ()
Hydroxylamine, N-(aminocarbonyl)- ()
N-Carbamoylhydroxylamine ()
N-Hydroxyurea ()
Hydroxyurea(d4) ()
Carbamoyl oxime ()
Hydroxyurea (D4) ()
Hydroxyurea (NSC-32065) ()
NCI-C04831, Hydroxycarbamide,NSC-32065 ()
SQ-1089 ()
Droxia ()
Siklos ()
SQ 1089 ()
NSC-32065 ()
P&D ID
PD002298
CAS
127-07-1
8029-68-3
Tags
available
drug
Approved by
EMA
FDA
First approval
1967
Drug Status
approved
Drug indication
Antineoplastic
Chronic myelogenous leukaemia
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Inhibits ribonucleoside-diphosphate reductase (RR1).
(GtoPdb)
TOXICITY
Oral, mouse: LD50 = 7330 mg/kg; Oral, rat: LD50 = 5760 mg/kg; Teratogenicity: Teratogenic effects have occurred in experimental animals.Hydroxyurea use during a small number of human pregnancies has been reported. Adverse effects have not been observed in any of the exposed newborns.; Reproductive Effects: Adverse reproductive effects have occurred in experimental animals.; Mutagenicity: Mutagenic effects have occurred in experimental animals.Mutagenic effects have occurred in humans.
DESCRIPTION
Antineoplastic; inactivates ribonucleoside reductase which blocks the synthesis of deoxynucleotides
(LOPAC library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
3
Organisms
2
Compound Sets
26
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
NIH Mechanistic Set
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
54
Molecular Weight
76.03
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
3
Rotatable Bonds
0
Ring Count
0
Aromatic Ring Count
0
cLogP
-0.96
TPSA
75.35
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
0.0
QED
0.26
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Ribonucleoside reductase
MOA
ribonucleoside-diphosphate reductase inhibitor
Nitric oxide donor
Ribonucleoside-Diphosphate Reductase Inhibitors
Antimetabolites
Ribonucleotide Reductase inhibitor
Target
Ribonucleoside-diphosphate reductase RR1
ribonucleoside diphosphate reductase
RRM1, RRM2, RRM2B
DNA/RNA Synthesis
HIV
Orthopoxvirus
Apoptosis related,Autophagy,DNA/RNA Synthesis,HIV
Pathway
DNA Damage/DNA Repair
Anti-infection
Apoptosis
Autophagy
Cell Cycle/DNA Damage
Member status
virtual
Indication
chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)
Disease Area
hematologic malignancy, oncology
Therapeutic Class
Anticancer Agents
Source data
